

Tucatinib MOUNTAINEER

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



QoL an exploratory endpoint



Serious and disabling adverse effects



Other adjustments



Tucatinib MOUNTAINEER

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers

Therapeutic Indication: Treatment of patients with RAS wild-type, HER2-positive unresectable or mCRC that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based ChT

Experimental Arm: Tucatinib + Trastuzumab

Control Arm: Single arm



